Analytical Data
-
Gene name
GALNS
- Application
-
Alternative Names
GALNS；N-acetylgalactosamine-6-sulfatase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P34059
-
Expression Region
1-522aa
-
AA Sequence
MAAVVAATRWWQLLLVLSAAGMGASGAPQPPNILLLLMDDMGWGDLGVYG EPSRETPNLDRMAAEGLLFPNFYSANPLCSPSRAALLTGRLPIRNGFYTT NAHARNAYTPQEIVGGIPDSEQLLPELLKKAGYVSKIVGKWHLGHRPQFH PLKHGFDEWFGSPNCHFGPYDNKARPNIPVYRDWEMVGRYYEEFPINLKT GEANLTQIYLQEALDFIKRQARHHPFFLYWAVDATHAPVYASKPFLGTSQ RGRYGDAVREIDDSIGKILELLQDLHVADNTFVFFTSDNGAALISAPEQG GSNGPFLCGKQTTFEGGMREPALAWWPGHVTAGQVSHQLGSIMDLFTTSL ALAGLTPPSDRAIDGLNLLPTLLQGRLMDRPIFYYRGDTLMAATLGQHKA HFWTWTNSWENFRQGIDFCPGQNVSGVTTHNLEDHTKLPLIFHLGRDPGE RFPLSFASAEYQEALSRITSVVQQHQEALVPAQPQLNVCNWAVMNWAPPG CEKLGKCLTPPESIPKKCLWSH
-
Molecular Weight
58 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GALNS (N-acetylgalactosamine-6-sulfatase) is a key enzyme involved in the lysosomal degradation of glycosaminoglycans, specifically in the metabolism of keratan sulfate and chondroitin sulfate. Deficiency in GALNS activity leads to mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, a rare genetic disorder characterized by skeletal abnormalities, joint stiffness, and other systemic issues. The study of GALNS protein is essential for understanding the molecular basis of MPS IV, which can provide insights into potential therapeutic approaches. Researchers have focused on the recombinant production of GALNS to explore its structure, function, and potential for enzyme replacement therapy. By utilizing techniques such as gene cloning, expression in heterologous systems, and purification, scientists aim to produce active GALNS protein for functional studies and preclinical trials. Investigating the biochemical properties of GALNS and understanding the impact of specific mutations on its activity can help in designing effective treatment strategies for affected individuals. Moreover, the recombinant GALNS can be instrumental in developing diagnostic tools for early detection of MPS IV. The exploration of GALNS not only enhances our comprehension of lysosomal storage disorders but also underscores the importance of biopharmaceutical advancements in addressing rare genetic conditions. Through ongoing research, there is hope for improved therapeutic options to manage MPS IV and enhance the quality of life for patients suffering from this debilitating disorder.
